UNITED THERAPEUTICS Corp (UTHR)

As of 14 August 2026, short interest in UTHR is 2,112,367 shares, up 23,619 shares over the last month. Over the last 48 readings it ranged from 1,565,617 shares (30 June 2025) to 4,087,057 shares (30 August 2024). At the reported average volume of 600K shares a day that is 3.5 days to cover.

<iframe src="https://xoomar.com/embed/stocks/uthr" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of UTHR volume is 54.5%, up 12.1 points over the last five sessions. Over the last 52 readings it ranged from 25.9% (14 July 2026) to 66.6% (21 July 2026). The latest reading is 4.7 points above the 30-session average of 49.8%, on 110K shares reported.

As of 7 August 2026, the fails-to-deliver balance in UTHR is 13 shares, down 9 shares over the last settlement date. Over the last 38 readings it ranged from 2 shares (13 March 2026) to 22,137 shares (16 December 2025). The latest reading sits at the bottom of that range.

Insiders at UTHR reported 221 open-market sells worth $106.1M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: ROTHBLATT MARTINE A (Chairperson & CEO) on 2026-09-10.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

6 Form 144 notices on file for UTHR worth $222.2M at the prices reported; 6 in the last 90 days worth $222.2M. Latest: PAUL MAHON filed on 2026-09-03 to sell 8,300 shares ($4.0M) from 2026-09-03.

8 of the 30 tracked managers held UTHR at their latest 13F, $2.08B in total at quarter-end prices. Renaissance Technologies is the largest at $925.8M (1.3% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) UNITED THERAPEUTICS Corp reported revenue of $783.3M, down 1.9% from the same quarter a year earlier, and net income of $333.0M (7.27 diluted EPS). In FY 2025 it generated $1.56B of operating cash flow and spent $1.00B on buybacks.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.